LP
Lipocine Inc.
LPCN · NASDAQ
$2.16 +0.00% (+$0.00)
1M +4.85%
Market Cap $17.8M
P/E Ratio -
Div. Yield -
ROE 64.75%
Bulios Fair Price
$1.69
21.8% downside
Current Price
$2.16
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LPCN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
50 /100
Fair P/S 11.35x
P/B 0.82x
P/E N/A
Growth
78 /100
Growing Rev. growth 58.12%
Book val. growth 25.94%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 98.10%
FCF margin 713.04%
Net margin 755.13%
Quality
1 /100
Poor ROIC 57.74%
Asset turnover 0.07x
ROE 64.75%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 11.48x
Int. coverage N/A
Stability
18 /100
Unstable Beta 0.47x
Profitable years 0
Rev. volatility 581.50%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LPCN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Mahesh V. Patel
Employees
14
Headquarters
Salt Lake City
Upcoming events
05 NOV
Earnings
Upcoming earnings report